| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
(Received for publication, March 23, 1995; and in revised form, July 12, 1995)
Recent in vitro work with Golgi-enriched membranes showed that 3`-azidothymidine-5`-monophosphate (AZTMP), the primary intracellular metabolite of 3`-azidothymidine (AZT), is a potent inhibitor of glycosylation reactions (Hall et al.(1994) J. Biol. Chem. 269, 14355-14358) and predicted that AZT treatment of whole cells should cause similar inhibition. In this report, we verify this prediction by showing that treatment of K562 cells with AZT inhibits lipid and protein glycosylation. AZT treatment dramatically alters the pattern of glycosphingolipid biosynthesis, nearly abolishing ganglioside synthesis at clinically relevant concentrations (1-5 µM), and suppresses the incorporation of both sialic acid and galactose into proteins. Control experiments demonstrate that these changes do not result from nonspecific effects on either the secretory apparatus or protein synthesis. On the other hand, studies using isolated nuclei as a model system for chromosomal DNA replication show that AZTTP is a very weak inhibitor of DNA synthesis. These observations strongly suggest that the myelosuppressive effects of AZT in vivo are due to inhibition of protein and/or lipid glycosylation and not to effects on chromosomal DNA replication.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  K. C. Lund, L. L. Peterson, and K. B. Wallace Absence of a Universal Mechanism of Mitochondrial Toxicity by Nucleoside Analogs Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2531 - 2539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lanteri, V. Giordanengo, N. Hiraoka, J.-G. Fuzibet, P. Auberger, M. Fukuda, L. G. Baum, and J.-C. Lefebvre Altered T cell surface glycosylation in HIV-1 infection results in increased susceptibility to galectin-1-induced cell death Glycobiology, December 1, 2003; 13(12): 909 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lavie, N. Ostermann, R. Brundiers, R. S. Goody, J. Reinstein, M. Konrad, and I. Schlichting Structural basis for efficient phosphorylation of 3'-azidothymidine monophosphate by Escherichia coli thymidylate kinase PNAS, November 24, 1998; 95(24): 14045 - 14050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Lavie, H.-t. Cao, A. Volner, A. Lucci, T.-Y. Han, V. Geffen, A. E. Giuliano, and M. C. Cabot Agents that Reverse Multidrug Resistance, Tamoxifen, Verapamil, and Cyclosporin A, Block Glycosphingolipid Metabolism by Inhibiting Ceramide Glycosylation in Human Cancer Cells J. Biol. Chem., January 17, 1997; 272(3): 1682 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Lavie, H.-t. Cao, S. L. Bursten, A. E. Giuliano, and M. C. Cabot Accumulation of Glucosylceramides in Multidrug-resistant Cancer Cells J. Biol. Chem., August 9, 1996; 271(32): 19530 - 19536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Steet, P. Melancon, and R. D. Kuchta 3'-Azidothymidine Potently Inhibits the Biosynthesis of Highly Branched N-Linked Oligosaccharides and Poly-N-acetyllactosamine Chains in Cells J. Biol. Chem., August 25, 2000; 275(35): 26812 - 26820. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
